U.S. Ambulatory Urology Devices Market: $9.29B by 2032

Market Outlook

By 2032, the U.S. Ambulatory Urology Devices Market is expected to reach approximately USD 9.29 billion, expanding at a CAGR of 9.65% during the forecast period 2027–2032. The market stood at USD 5.36 billion in 2026, building upon historical values of USD 4.12 billion in 2023, USD 4.49 billion in 2024, and USD 4.90 billion in 2025. Expressed in USD billions, these valuation baselines reflect the rapid migration of therapeutic and diagnostic urological interventions out of acute inpatient environments into lower-overhead, specialized outpatient facilities.

The U.S. ambulatory urology devices sector operates at the convergence of surgical technological miniaturization, dynamic clinical workflow economics, targeted Medicare site-of-service payment differentials, and an escalating national burden of urological pathologies. Demand across the United States is anchored by widespread clinical prevalence of benign prostatic hyperplasia, nephrolithiasis and ureterolithiasis, urinary incontinence, pelvic organ prolapse, overactive bladder, and non-muscle invasive bladder cancer. In 2024, more than 40 million American men exhibited clinical evidence of benign prostatic hyperplasia, with over 14 million actively seeking therapeutic or pharmaceutical management. Concurrently, nephrolithiasis affects approximately 11% of men and 7% of women in the United States at least once during their lifetime, producing over 1.3 million emergency department presentations and more than 450,000 surgical interventions annually.

Urinary stone disease has evolved into a recurring, resource-intensive outpatient operational category. Driven by metabolic syndromes, dietary shifts, geographic heat-index exposure, and systemic obesity, the domestic recurrence rate for urinary calculi surpasses 50% within five to seven years of an index event. This dynamic sustains recurring procedural utilization across disposable digital flexible ureteroscopes, holmium and thulium fiber laser platforms, nitinol stone extraction baskets, ureteral access sheaths, and double-J stents. In parallel, overactive bladder and stress urinary incontinence compromise the quality of life of more than 33 million Americans, spurring adoption of sacral neuromodulation implants, percutaneous tibial nerve stimulation arrays, suburethral sling systems, and outpatient periurethral bulking agents.

The marketplace is undergoing a decisive, value-based migration away from hospital inpatient suites toward ambulatory surgery centers and specialized office-based laboratory surgical suites. The integration of high-resolution digital chip-on-the-tip imaging, high-frequency dusting lasers, micro-invasive prostatic urethral lift implants, office-based transurethral water vapor ablation systems, and sterile single-use endoscopes has made complex endoscopic and ablative interventions clinically viable and economically profitable outside the acute hospital setting. Ambulatory platforms reduce total procedural duration, eliminate cross-contamination sterilization risks, and insulate practice revenues against hospital capital bottlenecks. Device manufacturers that align capital deployment models with per-case single-use disposable economics, comprehensive billing and coding assistance, and streamlined clinical instrumentation are outperforming vendors constrained by traditional capital equipment replacement cycles.

Historically, market revenue demonstrated steady post-pandemic normalization through 2023 and 2024 as ambulatory surgery centers addressed surgical backlogs, updated diagnostic visualization suites, and absorbed newly cleared minimally invasive technologies. Entering 2025 and 2026, growth transitioned toward volume-driven consumable utilization, high-frequency single-use digital ureteroscopy conversion, outpatient holmium-to-thulium laser upgrades, and rapid procedural scaling within office-based procedural suites. From 2027 through 2032, overall market trajectory will remain closely tied to continuous Medicare outpatient prospective payment system updates, ambulatory surgery center commercial payer parity, advancements in energy-based tissue vaporization, and the commercial maturation of non-surgical urology-focused private equity management networks.

Introduction

Ambulatory urology occupies a clinically distinctive position within the broader domestic medical device landscape due to its high procedure velocity, pronounced consumable turnover, and procedural migration velocity. A patient’s clinical journey typically initiates with diagnostic evaluations in an outpatient office—involving transurethral catheterization, automated uroflowmetry, bladder ultrasonography, or flexible diagnostic cystoscopy—before advancing to outpatient interventional management within an ambulatory surgery center or in-office procedure room. Interventions span laser lithotripsy, transurethral tissue resection or ablation, mid-urethral sling placement, and sacral neuromodulation lead implantation. This comprehensive care continuum drives a commercial model that marries durable benchtop capital equipment with high-margin, single-use consumable accessories.

Therapeutic instrumentation constitutes the operational cornerstone of this sector, generating approximately 64.3% of total U.S. ambulatory urology device revenue in 2025. This equipment class spans single-use and reusable digital endoscopes, intracorporeal lithotripters, surgical laser systems, mechanical and thermal tissue ablation platforms, mechanical retrieval baskets, guide wires, dilation balloons, and implantable continence prosthetics. The underlying revenue engine is commercially resilient: initial capital installations systematically pull through sustained demand for specialized access sheaths, laser delivery fibers, single-use continuous irrigation tubing, disposable biopsy forceps, and specialized retrieval devices.

Ambulatory surgery centers continue to command the primary market share for outpatient urological surgeries, capturing approximately 58.4% of total domestic demand under broad outpatient care classifications in 2025. This leadership is underpinned by the operational efficiency inherent to ambulatory facilities, including rapid operating room turnover times averaging under 15 minutes, dedicated surgical teams, lower overhead footprints, and favorable commercial insurance alignments. Concurrently, office-based urology suites are emerging as the fastest-growing procedural setting, driven by minimally invasive therapies for benign prostatic hyperplasia and diagnostic flexible cystoscopy that bypass the operational requirements of general anesthesia.

The procurement economics of ambulatory urology diverge substantially from acute inpatient hospital frameworks. Independent urology practices, private-equity-backed practice management organizations, and ambulatory surgery center joint-venture boards evaluate device acquisitions through immediate clinical workflow economics, chair time, room turnover velocity, sterilization turnaround costs, per-procedure consumable reimbursement margins, and short-term capital payback periods. Rather than managing lengthy multi-year capital budget cycles governed by administrative hospital committees, ambulatory decision-makers operate with commercial agility, demanding instrumentation that optimizes patient throughput, reduces postoperative monitoring requirements, and avoids capital-intensive reprocessing suites.

Reimbursement architecture serves as a central catalyst for ambulatory adoption. The Centers for Medicare & Medicaid Services continuously refines the Outpatient Prospective Payment System and the Ambulatory Surgical Center Payment System, creating deliberate incentives to transition selected diagnostic and therapeutic CPT codes into outpatient environments. Minimally invasive surgical therapies for benign prostatic hyperplasia, such as water vapor therapy and prostatic urethral lift, along with complex retrograde intrarenal surgeries utilizing flexible ureteroscopes, carry favorable ambulatory facility fee schedules that yield superior clinical margin profiles for independent surgeon-owners compared to hospital settings.

Operational compliance, environmental infection prevention, and reprocessing costs also play pivotal financial roles. Stringent standards for high-level disinfection and borescope inspections of flexible endoscopes have increased the total labor, compliance, and chemical footprint of reprocessing reusable devices. Documented contamination rates and reprocessing costs—ranging from USD 120 to USD 240 per procedure for reusable cystoscopes and ureteroscopes—have catalyzed widespread commercial conversion to sterile, single-use digital platforms. For high-volume ambulatory facilities, single-use platforms mitigate cross-contamination liability, protect device uptime, eliminate reprocessing bottlenecks, and transform unpredictable capital repair bills into predictable per-case expenses.

Looking ahead through the 2027–2032 forecast horizon, the most competitive ambulatory urology vendors will be those providing integrated procedural workflows. Superior commercial performance will belong to vendors that bundle therapeutic lasers with custom fiber delivery networks, pair single-use digital endoscopes with proprietary suction extraction sheaths, integrate cloud-based image archival platforms into practice-management software, and offer comprehensive clinical coding support to maximize provider economic efficiency across outpatient environments.

Key Market Drivers: What’s Fueling the U.S. Ambulatory Urology Devices Market Boom?

The rapid acceleration of the U.S. Ambulatory Urology Devices Market is anchored by an aging male demographic coupled with a rising national prevalence of benign prostatic hyperplasia. By 2026, the domestic population aged 65 and older exceeds 58 million individuals, a demographic wherein the histological incidence of prostatic enlargement approaches 80%. This massive clinical cohort increasingly rejects life-long medical therapies—such as alpha-blockers and 5-alpha-reductase inhibitors—due to systemic adverse effects, including orthostatic hypotension, retrograde ejaculation, and cognitive fatigue. Consequently, patient demand has pivoted toward minimally invasive surgical therapies that can be deployed under local anesthesia within outpatient or office-based settings, generating sustained consumable volume for implants, tissue delivery cannulas, and single-use delivery devices.

A second structural driver is the clinical and logistical revolution sweeping nephrolithiasis management. Modern outpatient stone surgery has shifted toward retrograde intrarenal surgery leveraging single-use flexible digital ureteroscopes, high-wattage holmium:YAG lasers with pulse-modulation technology, and compact thulium fiber lasers. Outpatient lithotripsy protocols prioritize dusting techniques that pulverize stones into micro-particles smaller than one millimeter, mitigating the necessity for tedious basket extraction and reducing surgical durations by 25% to 40%. This technological shift permits immediate post-procedural discharge, diminishes postoperative stent distress, and encourages ambulatory surgery centers to expand their urological case allocation.

A third major catalyst involves the targeted alignment of Medicare and commercial reimbursement structures favoring outpatient migration. CMS continues to evaluate and rebalance outpatient prospective payment schedules and ASC covered surgical procedures lists. Substantial facility fee differentials between acute hospital inpatient settings and ambulatory sites have prompted both independent urology practices and corporate hospital systems to construct ambulatory surgery center joint ventures. In tandem, modern coding pathways for office-based prostatic tissue ablation, balloon dilation of the prostate, and sacral nerve stimulation lead implantation provide sustainable practice economics, accelerating the acquisition of office-based capital equipment and disposable instrumentation.

The rapid operational transition from reusable endoscopes to sterile single-use visualization systems represents a fourth critical growth engine. Rigid and flexible endoscope reprocessing has encountered heightened scrutiny across domestic healthcare facilities due to persistent challenges with bacterial bio-burden retention, channel degradation, and sterilization logistics. Reusable flexible ureteroscopes generally require expensive mechanical repairs every 8 to 15 clinical cases, incurring substantial maintenance expenditures and creating operational friction. Single-use digital cystoscopes and ureteroscopes eliminate equipment downtime, guarantee pristine optical resolution and maximum mechanical articulation for every intervention, and transfer capital line-item depreciation into predictable per-procedure operational expenses reimbursed under specialized ambulatory arrangements.

Fifth, private equity consolidation across the domestic urology landscape is transforming clinical procurement behavior. Large urology group practices and clinical networks have expanded aggressively across key metropolitan and secondary markets. These corporate entities operate with advanced financial discipline, actively optimizing procedural throughput, negotiating volume-tier enterprise purchasing agreements with medical device manufacturers, and building centralized ambulatory surgical centers and office-based suites. By standardizing device fleets, insourcing pathology and diagnostic imaging, and concentrating surgical volume within their proprietary outpatient facilities, private equity platforms are amplifying capital and consumable expenditure on dedicated ambulatory urology technologies.

Sixth, continuous innovation in device miniaturization, ergonomics, and smart-sensor integration is lowering the threshold of surgical invasiveness. The introduction of steerable access sheaths with continuous real-time intrarenal pressure monitoring has enhanced surgical safety during ambulatory stone vaporization, reducing the risk of postoperative sepsis and fluid extravasation. Concurrently, minimally invasive surgical therapy implants designed for benign prostatic hyperplasia feature lower profile mechanical delivery systems that facilitate rapid deployment under basic oral sedation and local prostatic blocks, allowing patients to ambulate and return home within hours without requiring urinary catheterization.

Finally, patient consumerism and preference for rapid convalescence are reshaping treatment pathways. Contemporary healthcare consumers actively avoid inpatient hospital environments to minimize nosocomial infection risks and reduce out-of-pocket deductibles. The prospect of receiving an intervention for urinary tract obstruction, incontinence, or nephrolithiasis within an ambulatory surgical suite, recovering in a calm setting, and resuming professional and personal activities within 24 to 48 hours has created organic patient pull-through. This demand curve encourages ambulatory operators to invest in cutting-edge, patient-friendly diagnostic and therapeutic urology platforms.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation across the U.S. ambulatory urology devices sector is centered on enhancing procedural predictability, shrinking equipment footprints, shortening operating room occupancy, and engineering single-use platforms that match or exceed the optical and mechanical characteristics of legacy reusable systems. The commercial focus has moved past incremental improvements in mechanical handpieces toward holistic technological ecosystems that combine high-definition digital visualization, intelligent energy delivery, real-time physiological feedback, and optimized single-use supply chains.

Single-use digital ureteroscopy platforms illustrate this technological progression. Advanced single-use ureteroscopes incorporate high-resolution CMOS micro-imaging sensors directly on the distal tip, integrated LED illumination channels, and dynamic 270-degree bidirectional deflection capabilities. These single-use scopes boast reduced outer sheath calibers down to 7.5 French while maintaining 3.6 French working channels, accommodating simultaneous fiber laser passage and continuous fluid irrigation. High-speed digital processors interface seamlessly with mobile monitor towers or tablet-sized display consoles, eliminating the massive footprint and capital overhead of legacy operating room endoscopic video racks.

Laser technology has undergone a parallel transition, led by the commercial ascent of thulium fiber laser systems and pulse-modulated holmium:YAG platforms. Thulium fiber laser technology utilizes an active silica fiber doped with thulium ions, excited by laser diode banks, emitting at a wavelength of 1,940 nanometers. This aligns directly with the peak absorption of water in human tissue, resulting in a minimal water absorption depth of just 0.1 millimeters. In ambulatory lithotripsy, this enables ultra-fine stone dusting at high pulse frequencies exceeding 2,000 Hertz, generating microscopic fragments that pass spontaneously while minimizing stone retropulsion. The compact, air-cooled architecture of thulium systems requires standard 120-volt electrical connectivity, fitting standard outpatient procedure rooms without expensive electrical upgrades.

Minimally invasive benign prostatic hyperplasia surgical devices have redefined clinical treatment algorithms. Modern platforms utilize localized therapeutic mechanisms—such as transurethral convective water vapor thermal energy, permanent nitinol prostatic urethral lift implants, and temporary implantable nitinol devices—to rapidly debulk or mechanically reconfigure the transitional zone of the prostate. These platforms operate via single-use, pre-loaded ergonomic delivery handpieces deployed through standard cystoscopic sheaths. By avoiding electrical tissue cutting and deep thermal necrosis, these innovations spare sexual function, preserve urinary continence, eliminate requirements for postoperative continuous bladder irrigation, and permit immediate patient discharge.

In the management of voiding dysfunction and urinary incontinence, innovation is marked by miniaturization, battery longevity, and micro-invasive implantation workflows. Sacral neuromodulation platforms feature rechargeable micro-stimulators smaller than three cubic centimeters with operational lifespans exceeding 15 years, alongside advanced primary-cell, recharge-free stimulators that run uninterrupted for over a decade. Concurrently, percutaneous tibial nerve stimulation has evolved from rigid clinical office visits into miniaturized, implantable sub-fascial arrays and wearable transcutaneous systems, expanding non-pharmacological therapies for overactive bladder throughout ambulatory environments.

Diagnostic urodynamics and in-office evaluation technologies are experiencing a digital transformation. Legacy multi-channel urodynamic systems required complex fluid-filled pressure transducers, intensive calibration, and bulky examination chairs. Modern ambulatory systems leverage wireless, air-charged or micro-transducer catheter technology coupled via Bluetooth to compact diagnostic tablets. Cloud-based analytical algorithms automatically compute compliance, detrusor pressure curves, and flow-rate metrics, flagging subtle detrusor overactivity and bladder outlet obstruction patterns while reducing examination durations by more than 30%.

Finally, the convergence of artificial intelligence and computer-assisted visualization is entering the ambulatory urology theater. Cloud-connected cystoscopy platforms employ real-time image analysis algorithms during diagnostic procedures to assist urologists in identifying subtle erythematous mucosal anomalies, carcinoma in situ, and recurrent non-muscle invasive bladder cancer lesions. By standardizing diagnostic visual fields, enhancing documentation through automated report compilation, and reducing missed pathology rates, these software-enhanced platforms elevate clinical diagnostic confidence across high-volume outpatient surgical centers.

Segmentation Insights

The U.S. Ambulatory Urology Devices Market is segmented on the basis of product category, clinical indication, procedure type, site of care, and workflow configuration.

By Product Category

Endoscopes & Visualization Systems
Endoscopes and visualization platforms represent the largest core technology segment in ambulatory urology, accounting for USD 1.48 billion in 2026, after recording USD 1.12 billion in 2023, USD 1.23 billion in 2024, and USD 1.35 billion in 2025. This product group is projected to achieve USD 2.65 billion by 2032, advancing at a CAGR of 10.19% during the 2027–2032 forecast window.

The category encompasses flexible digital single-use ureteroscopes, flexible and rigid cystoscopes, video resectoscopes, digital nephroscopes, compact HD/4K camera processors, and mobile display units. Operational growth is led by the rapid conversion of diagnostic cystoscopy and retrograde intrarenal surgery from fragile reusable endoscopes to single-use platforms. Single-use scopes eliminate capital repairs, guarantee sterility, and ensure unobstructed working channels for high-frequency ambulatory operating rooms.

Urological Lasers & Lithotripsy Systems
Urological lasers and lithotripsy systems generated USD 0.95 billion in 2026, rising from USD 0.74 billion in 2023, USD 0.80 billion in 2024, and USD 0.87 billion in 2025. The category is projected to reach USD 1.63 billion by 2032, expanding at a CAGR of 9.42% from 2027 to 2032.

The segment comprises high-power holmium:YAG lasers with advanced pulse modulation, thulium fiber lasers, intracorporeal pneumatic and ultrasonic lithotripters, and compact extracorporeal shock wave lithotripsy units. Clinical utilization is driven by the ascendancy of fine dusting algorithms in stone surgery, which pulverize calcium oxalate and uric acid stones into sub-millimeter fragments. Thulium fiber lasers are expanding rapidly across outpatient settings due to their compact footprint, wall-outlet power compatibility, and precise soft-tissue vaporization capabilities.

Minimally Invasive BPH Surgical Devices
Minimally invasive benign prostatic hyperplasia surgical devices represent the fastest-expanding product category, reaching USD 1.05 billion in 2026, following historical valuations of USD 0.76 billion in 2023, USD 0.85 billion in 2024, and USD 0.95 billion in 2025. The market is positioned to reach USD 1.96 billion by 2032, demonstrating a market-leading CAGR of 11.00% over the forecast duration.

This category includes convective water vapor thermal delivery platforms, permanent prostatic urethral lift implants, temporary nitinol expansion baskets, transurethral microwave antennae, and robotic waterjet resection accessories. The sector benefits from patient demand for rapid, ejaculation-sparing treatments that can be completed within 15 minutes under local anesthesia, driving high-margin single-use device sales across outpatient and office settings.

Dialysis & Urinary Drainage Catheters / Stents
Dialysis access products, drainage catheters, and internal stents generated USD 0.81 billion in 2026, after logging USD 0.65 billion in 2023, USD 0.70 billion in 2024, and USD 0.75 billion in 2025. This stable consumable segment is forecasted to attain USD 1.30 billion by 2032, reflecting a CAGR of 8.21% between 2027 and 2032.

The category includes hydrophilic-coated double-J ureteral stents, magnetic-tip stent extraction systems, percutaneous nephrostomy catheterization sets, intermittent hydrophilic Foley catheters, and specialized peritoneal dialysis access ports. Growth is sustained by high baseline procedural turnover, where every endourological stone extraction, ureteral stricture dilation, or acute obstruction intervention requires downstream placement of internal stents and drainage lines.

Urodynamics & Diagnostic Systems
Urodynamic examination consoles, digital uroflowmeters, and ultrasound bladder scanners recorded USD 0.49 billion in 2026, rising from USD 0.40 billion in 2023, USD 0.43 billion in 2024, and USD 0.46 billion in 2025. The segment is anticipated to reach USD 0.78 billion by 2032, progressing at a CAGR of 8.07% over the forecast timeframe.

The category spans wireless multi-channel urodynamics workstations, air-charged physiological catheters, EMG sensory surface arrays, portable 3D bladder volume scanners, and cloud-integrated uroflowmetry basins. Procurement is driven by the expansion of specialized voiding dysfunction clinics, where accurate, non-invasive, point-of-care diagnostics are mandated by commercial payers prior to authorizing advanced surgical interventions.

Urinary Incontinence & Pelvic Floor Devices
Urinary incontinence and pelvic floor reconstruction devices attained USD 0.58 billion in 2026, building upon historical values of USD 0.45 billion in 2023, USD 0.49 billion in 2024, and USD 0.53 billion in 2025. This therapeutic segment is projected to total USD 0.97 billion by 2032, charting a CAGR of 9.00% across the 2027–2032 projection window.

The product category incorporates sacral neuromodulation pulse generators, percutaneous tibial nerve stimulator kits, synthetic mid-urethral slings, artificial urinary sphincters, and injectable periurethral bulking hydrogels. Segment expansion is propelled by aging demographics and the growing adoption of rechargeable and recharge-free neuromodulation platforms implanted in outpatient surgery centers under light conscious sedation.

By Clinical Indication

Benign Prostatic Hyperplasia (BPH)
Benign prostatic hyperplasia represents the largest clinical indication, capturing USD 1.83 billion in 2026, after registering USD 1.37 billion in 2023, USD 1.51 billion in 2024, and USD 1.66 billion in 2025. It is on track to reach USD 3.26 billion by 2032, progressing at a CAGR of 10.11% from 2027 to 2032.

The dominance of BPH stems from its massive demographic footprint, affecting over 50% of American men in their sixties and up to 90% of men in their eighties. Clinical treatment protocols have transitioned away from inpatient transurethral resection of the prostate requiring days of catheterization toward outpatient convective water vapor ablation, prostatic urethral lifting, and laser enucleation, driving continuous utilization of single-use delivery devices.

Urolithiasis / Nephrolithiasis
Urinary calculi management generated USD 1.64 billion in 2026, rising from USD 1.28 billion in 2023, USD 1.39 billion in 2024, and USD 1.51 billion in 2025. The indication is projected to achieve USD 2.86 billion by 2032, expanding at a CAGR of 9.73% during the forecast period.

Nephrolithiasis drives consistent procedural volume in ambulatory surgery centers due to high prevalence in the southern stone belt, rising metabolic syndrome rates, and lifetime stone recurrence rates exceeding 50%. Outpatient retrograde intrarenal surgery leveraging single-use digital ureteroscopes, thulium fiber lasers, and steerable suction access sheaths maintains steady consumable turnover.

Urinary Incontinence & Voiding Dysfunction
Urinary incontinence and voiding dysfunction indications accounted for USD 0.96 billion in 2026, following historical performance of USD 0.74 billion in 2023, USD 0.81 billion in 2024, and USD 0.88 billion in 2025. This sector is expected to reach USD 1.63 billion by 2032, advancing at a CAGR of 9.20% through 2032.

Affecting more than 33 million Americans, overactive bladder, stress urinary incontinence, and neurogenic detrusor overactivity generate substantial device demand. Outpatient therapeutic approaches feature sacral neuromodulation lead placements, minimally invasive synthetic sling tensioning, transurethral hydrogel bulking, and multi-channel urodynamic evaluations, driving steady consumable and implant deployment.

Urological Oncology
The ambulatory urological oncology segment accounted for USD 0.52 billion in 2026, up from USD 0.40 billion in 2023, USD 0.44 billion in 2024, and USD 0.48 billion in 2025. It is forecasted to reach USD 0.89 billion by 2032, registering an 9.36% CAGR from 2027 to 2032.

Activity centers on the diagnosis, surveillance, and localized therapy of non-muscle invasive bladder cancer, upper tract urothelial carcinoma, and low-grade prostate lesions. Outpatient workflows rely on high-definition flexible cystoscopy, blue-light visualization catheters, transurethral biopsy forceps, focal cryoablation probes, and in-office intravesical chemo-hyperthermia delivery systems.

Chronic Kidney Disease, Strictures & Other Disorders
Ureteral strictures, chronic renal disorders, pelvi-ureteric junction obstructions, and related pathologies accounted for USD 0.41 billion in 2026, following historical milestones of USD 0.33 billion in 2023, USD 0.35 billion in 2024, and USD 0.38 billion in 2025. The sector is positioned to attain USD 0.65 billion by 2032, delivering an 8.01% CAGR across the forecast span.

Clinical applications encompass outpatient endoureterotomy, cutting-balloon dilation, specialized metal and polymer resonance stent insertions, and peritoneal dialysis catheter placements, driving continuous demand for precision access wires, high-pressure dilation balloons, and long-term drainage assemblies.

By Procedure Type

Ureteroscopy & Intracorporeal Lithotripsy
Ureteroscopy and laser lithotripsy procedures generated USD 1.55 billion in 2026, rising from USD 1.20 billion in 2023, USD 1.30 billion in 2024, and USD 1.42 billion in 2025. The segment is projected to reach USD 2.73 billion by 2032, advancing at a CAGR of 9.89% between 2027 and 2032.

This procedure is the gold standard for kidney and ureteral stone management across American outpatient facilities. Growth is accelerated by single-use digital ureteroscopes, fine dusting with high-frequency thulium and holmium lasers, and vacuum-assisted stone aspiration sheaths, which together maximize stone clearance rates in a single ambulatory setting.

Transurethral Resection, Enucleation & Ablation
Transurethral anatomical tissue removal—encompassing bipolar TURP, holmium laser enucleation of the prostate, and photoselective vaporization—recorded USD 1.18 billion in 2026, following USD 0.94 billion in 2023, USD 1.01 billion in 2024, and USD 1.09 billion in 2025. The segment is expected to reach USD 1.98 billion by 2032, registering an 8.99% CAGR over the forecast timeline.

While historically requiring hospital admission, modern plasma-button bipolar resection and high-power laser enucleation technologies feature superior intraoperative hemostasis, enabling urologists to treat large-volume prostates within ambulatory surgical centers with same-day catheter removal.

Office-Based BPH Interventions
Micro-invasive office-based benign prostatic hyperplasia procedures generated USD 0.91 billion in 2026, up from USD 0.64 billion in 2023, USD 0.72 billion in 2024, and USD 0.81 billion in 2025. The procedure class is anticipated to achieve USD 1.77 billion by 2032, demonstrating an industry-leading CAGR of 11.73% during 2027–2032.

Encompassing transurethral water vapor thermal therapy, prostatic urethral lifting, and temporary nitinol basket expansion, these procedures bypass operating room anesthesia. Performed in specialized office procedure suites under local prostatic blocks in under 20 minutes, these interventions offer streamlined patient convalescence and favorable in-office practice economics.

Diagnostic Cystoscopy & Biopsy
Outpatient diagnostic cystoscopy, mucosal surveillance, and biopsy procedures generated USD 0.75 billion in 2026, rising from USD 0.60 billion in 2023, USD 0.65 billion in 2024, and USD 0.70 billion in 2025. The segment is projected to total USD 1.23 billion by 2032, expanding at a CAGR of 8.60% across the forecast period.

Performing millions of evaluations annually for hematuria, recurrent infection, and bladder cancer surveillance, this procedure represents high clinical volume. The transition toward sterile single-use digital cystoscopes with integrated LED illumination eliminates reprocessing wait times, enhances diagnostic yield, and drives high consumable throughput.

Neuromodulation & Anti-Incontinence Implants
Neuromodulation lead placements, male/female sling tensioning, and artificial sphincter implantations reached USD 0.59 billion in 2026, after logging USD 0.45 billion in 2023, USD 0.49 billion in 2024, and USD 0.54 billion in 2025. This procedure category is slated to achieve USD 1.00 billion by 2032, charting a CAGR of 9.20% from 2027 to 2032.

Growth is driven by standardized, micro-invasive outpatient workflows for sacral nerve stimulator trials and permanent implants. Using local anesthesia and light sedation within ambulatory surgery centers, surgeons achieve precise electrode placement in under 45 minutes, fostering same-day recovery.

Urodynamic Evaluations & Non-Invasive Diagnostics
Urodynamic studies, comprehensive pressure-flow assessments, and point-of-care bladder scanning generated USD 0.38 billion in 2026, climbing from USD 0.30 billion in 2023, USD 0.32 billion in 2024, and USD 0.35 billion in 2025. The category is projected to reach USD 0.59 billion by 2032, reflecting a CAGR of 7.60% through 2032.

These evaluations are foundational for differential diagnosis of complex voiding pathologies. Uptake of wireless, air-charged diagnostic catheters and software-guided analysis platforms has streamlined execution, allowing outpatient practices to perform high-throughput assessments that fulfill payer pre-authorization mandates.

By Site of Care

Ambulatory Surgery Centers (ASCs)
Ambulatory surgery centers constitute the dominant site of care, generating USD 3.13 billion in 2026, building upon historical foundations of USD 2.39 billion in 2023, USD 2.61 billion in 2024, and USD 2.85 billion in 2025. ASC demand is projected to reach USD 5.51 billion by 2032, recording a CAGR of 9.89% across the 2027–2032 projection window.

ASCs represent the primary operational environment for complex outpatient urology, including retrograde intrarenal laser lithotripsy, transurethral prostate enucleation, neuromodulation, and sling placements. Their commercial strength stems from specialized surgical staffing, room turnover times under 15 minutes, physician-ownership alignment, and favorable reimbursement structures relative to acute inpatient facilities.

Hospital Outpatient Departments (HOPDs)
Hospital outpatient departments generated USD 1.23 billion in 2026, following historical performance of USD 0.99 billion in 2023, USD 1.07 billion in 2024, and USD 1.14 billion in 2025. The segment is projected to achieve USD 1.95 billion by 2032, reflecting a CAGR of 8.01% over the forecast period.

HOPDs retain vital market share by treating medically complex, high-acuity patients who require outpatient urological interventions but possess significant cardiopulmonary comorbidities. Health systems continue to channel outpatient capital into HOPDs, standardizing surgical visualization towers and lasers to preserve procedural revenues within the health system network.

Urology Clinics & Office-Based Surgical Suites
Urology clinics and dedicated office-based surgical suites represent the fastest-growing site of care, reaching USD 0.75 billion in 2026, up from USD 0.54 billion in 2023, USD 0.60 billion in 2024, and USD 0.67 billion in 2025. This sector is projected to reach USD 1.45 billion by 2032, advancing at an exceptional CAGR of 11.60% between 2027 and 2032.

Driven by private equity practice roll-ups and physician-owner economics, urologists are actively transitioning diagnostic cystoscopies, urodynamics, and micro-invasive BPH therapies into accredited office surgical suites. Bypassing the facility fees of ASCs and hospitals, office suites provide maximum convenience for patients and superior margin capture for practitioners.

Specialized Kidney Stone & Dialysis Centers
Specialized outpatient lithotripsy centers and vascular/peritoneal dialysis access facilities generated USD 0.25 billion in 2026, after logging USD 0.20 billion in 2023, USD 0.21 billion in 2024, and USD 0.23 billion in 2025. The category is forecasted to attain USD 0.38 billion by 2032, advancing at a CAGR of 7.23% through 2032.

These dedicated facilities specialize in rapid-access shock wave lithotripsy, routine endourological stent exchanges, and peritoneal dialysis catheter maintenance, prioritizing high case turnover and dedicated procedural protocols.

By Workflow Configuration

Single-Use / Disposable Urological Devices
Single-use disposable instruments represent the operational vanguard of ambulatory workflow, generating USD 2.09 billion in 2026, following historical milestones of USD 1.54 billion in 2023, USD 1.70 billion in 2024, and USD 1.88 billion in 2025. The segment is expected to reach USD 3.82 billion by 2032, registering a market-leading CAGR of 10.57% during 2027–2032.

This category includes single-use digital flexible ureteroscopes, disposable cystoscopes, biopsy forceps, laser fibers, stone retrieval baskets, and guide wires. The commercial shift is driven by the total elimination of scope reprocessing costs, mitigation of cross-infection risks, and eradication of equipment downtime in fast-paced ambulatory surgery centers.

Reusable Capital Systems & Handpieces
Reusable capital consoles and surgical handpieces recorded USD 1.45 billion in 2026, up from USD 1.18 billion in 2023, USD 1.26 billion in 2024, and USD 1.35 billion in 2025. The segment is projected to achieve USD 2.30 billion by 2032, demonstrating a 8.00% CAGR over the forecast timeline.

Comprising holmium:YAG and thulium fiber laser consoles, plasma energy generators, mobile C-arm fluoroscopy interfaces, and modular urodynamic towers, these durable assets form the core infrastructure of outpatient surgical suites. Manufacturers compete through compact machine dimensions, standard electrical requirements, and low maintenance overhead.

Office-Integrated Diagnostic & Procedural Platforms
Office-integrated diagnostic and treatment platforms accounted for USD 0.91 billion in 2026, climbing from USD 0.68 billion in 2023, USD 0.75 billion in 2024, and USD 0.83 billion in 2025. The category is projected to reach USD 1.66 billion by 2032, expanding at a CAGR of 10.54% between 2027 and 2032.

These platforms encompass all-in-one cart systems combining LED light sources, digital tablet displays, video recording software, and sterile fluid irrigation systems tailored for office-based cystoscopy, water vapor ablation, and diagnostic examinations without complex operating room overhead.

Consumables, Access Sheaths & Retrieval Accessories
Specialized consumable accessories accounted for USD 0.91 billion in 2026, building upon historical values of USD 0.72 billion in 2023, USD 0.78 billion in 2024, and USD 0.84 billion in 2025. The category is slated to achieve USD 1.51 billion by 2032, reflecting a CAGR of 8.81% across the forecast duration.

Encompassing ureteral access sheaths with continuous suction capabilities, dual-lumen dilation catheters, guidewires, continuous irrigation fluid sets, and double-J stents, these consumable items guarantee dependable recurring revenue streams for every surgical procedure performed.

Regional Insights: Where the Market is Growing Fastest

The U.S. Ambulatory Urology Devices Market is geographically divided into four primary regions: the South, the West, the Midwest, and the Northeast. Regional demand is shaped by localized demographic aging curves, the geographic incidence of urinary calculi, private equity urology practice consolidation, state-level certificate-of-need regulatory hurdles, ambulatory surgery center penetration, and commercial payer coverage policies.

The South represents the largest commercial market, driven by population growth and the geographical concentration of kidney stone disease. The West is projected to achieve the highest technology-driven growth rate through 2032, spurred by rapid ambulatory migration and venture-backed healthcare innovation. The Northeast demonstrates high device expenditure driven by complex oncology protocols and academic outpatient networks, while the Midwest combines stable demographic disease burden with deep health-system outpatient consolidation.

South

The South constitutes the largest regional market for ambulatory urology devices, generating USD 1.98 billion in 2026, following historical performance of USD 1.50 billion in 2023, USD 1.64 billion in 2024, and USD 1.80 billion in 2025. The region is positioned to reach USD 3.52 billion by 2032, progressing at a CAGR of 10.08% across the forecast period.

The region’s market leadership is anchored by its position within the domestic “Kidney Stone Belt,” where elevated mean annual temperatures, chronic dehydration, metabolic syndrome, and dietary factors drive nephrolithiasis rates 30% to 50% above the national baseline. This clinical reality drives continuous, high-volume demand for retrograde intrarenal surgery, single-use digital ureteroscopes, holmium and thulium dusting lasers, nitinol retrieval baskets, and ureteral access sheaths. Furthermore, the South contains rapidly expanding retirement destinations characterized by high concentrations of elderly males with symptomatic benign prostatic hyperplasia and overactive bladder, fostering adoption of outpatient ablative systems and sacral neuromodulation implants.

Texas serves as a cornerstone of southern market volume, generating substantial device demand across expansive metropolitan healthcare systems in Houston, Dallas-Fort Worth, Austin, and San Antonio. The state’s business-friendly regulatory framework, marked by the absence of restrictive certificate-of-need laws for ambulatory surgery centers, has catalyzed aggressive construction of independent and physician-joint-venture surgical facilities. More than 3.2 million adult men in Texas suffer from symptomatic BPH, generating rapid utilization of transurethral convective water vapor systems and prostatic urethral lift implants within office-based and ASC suites. Furthermore, metropolitan Texas hosts extensive private-equity-backed urology networks that negotiate volume-tiered procurement contracts for single-use flexible ureteroscopes, standardizing outpatient fleets.

Florida represents another high-value state market, distinguished by the nation’s highest concentration of Medicare beneficiaries per capita. With over 4.6 million residents aged 65 and older, Florida clinicians manage vast cohorts of geriatric patients with benign prostatic enlargement, bladder outlet obstruction, urinary incontinence, and non-muscle invasive bladder cancer. Outpatient surgical centers throughout Tampa-St. Petersburg, Miami-Fort Lauderdale, Orlando, and Jacksonville process elevated daily volumes of diagnostic cystoscopies, laser enucleation procedures, and suburethral sling tensioning. The state’s demographic profile makes it an essential proving ground for miniature, recharge-free sacral neuromodulation systems and non-invasive point-of-care urodynamic evaluation suites.

North Carolina and Georgia are experiencing rapid market expansion driven by population in-migration, robust corporate health system networks, and the expansion of specialized outpatient surgical centers throughout the Research Triangle, Charlotte, and metropolitan Atlanta. Adult stone incidence in North Carolina exceeds 12%, driving intense utilization of holmium:YAG laser platforms and outpatient shock wave lithotripters. Major academic medical networks in both states are actively divesting routine endourological interventions out of tertiary hospital operating rooms into regional ambulatory networks, standardizing single-use visualization suites to optimize room turnaround times.

Tennessee, Virginia, Louisiana, Alabama, and South Carolina add significant depth to the southern market. Tennessee benefits from Nashville’s position as a national healthcare management hub, housing major corporate ambulatory surgery center operators that evaluate and standardize urological instrumentation portfolios nationwide. In rural and non-metropolitan districts across Alabama, Mississippi, and South Carolina, where access to tertiary hospital facilities is constrained, mobile lithotripsy provider routes and specialized outpatient clinics provide essential endourological care, creating consistent regional demand for compact, transportable laser systems and durable drainage consumables.

West

The West represents the fastest-growing regional market in the United States, valued at USD 1.39 billion in 2026, after recording USD 1.05 billion in 2023, USD 1.15 billion in 2024, and USD 1.26 billion in 2025. It is projected to reach USD 2.50 billion by 2032, expanding at an industry-leading CAGR of 10.28% between 2027 and 2032.

Regional expansion is driven by progressive commercial payer integration, dense networks of physician-led surgical joint ventures, early clinical adoption of digital health platforms, and consumer preferences for minimally invasive, same-day surgical care. The West exhibits high penetration rates for single-use digital endoscopes and advanced thulium fiber lasers, with regional surgical boards prioritizing technologies that eliminate scope reprocessing footprint, reduce chemical exposure, and support rapid operating room turnover.

California commands the largest operational volume in the West, driven by its population of nearly 39 million residents, expansive healthcare systems, and concentrated medical technology research centers. Major metropolitan healthcare centers across Los Angeles, Orange County, San Diego, and the San Francisco Bay Area are converting high-volume diagnostic cystoscopy from reusable scopes to single-use digital platforms. California’s commercial insurance landscape strongly favors procedures performed in accredited outpatient surgical suites over hospital settings, providing lucrative facility reimbursements for office-based prostatic tissue ablation and retrograde intrarenal surgery. Urology practices throughout the state actively invest in compact thulium fiber laser systems that utilize standard electrical connections, optimizing outpatient procedure space.

Washington and Oregon represent technologically progressive outpatient urology environments. Seattle’s advanced healthcare networks and research institutions have embraced digital single-use flexible ureteroscopes, vacuum-assisted access sheaths, and cloud-connected urodynamics. Independent urology alliances across the Pacific Northwest are at the forefront of establishing specialized stone clinics and pelvic floor restoration centers, deploying office-based tibial nerve stimulation platforms and minimally invasive surgical therapy implants. The regional focus on sustainability and clinical efficiency makes single-use endoscope recycling programs and low-energy consoles commercially compelling for institutional procurement boards.

Arizona and Nevada represent rapidly growing markets characterized by an influx of retirees and expanding specialized outpatient infrastructure. The Phoenix-Scottsdale metropolitan corridor, Tucson, and Las Vegas are seeing rapid development of standalone ambulatory surgery centers and office procedure rooms. The high regional prevalence of heat-related nephrolithiasis and an aging demographic with lower urinary tract symptoms drive procedural velocity for laser lithotripsy and minimally invasive BPH implants. Regional facilities prioritize high-power dusting lasers and pre-packaged single-use delivery devices that maximize procedural volumes without straining small clinical support teams.

Colorado, Utah, Idaho, and New Mexico contribute substantial dynamism to the Western territory. Colorado and Utah feature high concentrations of active, insured individuals who prefer fast outpatient convalescence, accelerating the shift away from inpatient open or transurethral resections toward minimally invasive therapies for BPH and stone management. Denver and Salt Lake City have emerged as key centers for outpatient surgical training, where regional clinicians adopt steerable ureteral access sheaths with intrarenal pressure monitoring to maximize patient safety during ambulatory lithotripsy.

Midwest

The Midwest represents an operationally resilient and demographically mature market, valued at USD 1.13 billion in 2026, after logging USD 0.89 billion in 2023, USD 0.96 billion in 2024, and USD 1.04 billion in 2025. The market is forecasted to attain USD 1.90 billion by 2032, advancing at a CAGR of 9.05% over the forecast timeframe.

The region combines a substantial elderly population with high rates of obesity, diabetes, and cardiovascular comorbidities that contribute to urolithiasis and bladder dysfunction. While hospital systems traditionally dominated healthcare delivery in the Midwest, large integrated delivery networks across the region are systematically developing off-campus ambulatory surgery center networks to lower care delivery costs and counter private surgical center competition.

Illinois serves as a primary driver of Midwestern demand, anchored by metropolitan Chicago’s massive concentration of academic medical centers, suburban hospital networks, and independent urology practices. Illinois urologists have been early adopters of high-power laser enucleation platforms and micro-invasive BPH therapies. Regional surgical suites process significant daily volumes of transurethral water vapor thermal ablation and prostatic urethral lift interventions. The competitive payer landscape in Chicago incentivizes commercial ambulatory surgery centers to procure dual-action lithotripsy systems and single-use endoscopes that minimize turnover intervals, maximizing surgical volume per room per day.

Ohio represents an equally significant market, driven by prominent health systems located in Cleveland, Columbus, Cincinnati, and Dayton. Integrated health systems across Ohio have shifted diagnostic cystoscopies, routine double-J stent exchanges, and uncomplicated ureteroscopies entirely out of inpatient hospital towers into regional outpatient health centers. Over 1.3 million adult men in Ohio suffer from clinical BPH, sustaining steady consumable utilization across mechanical tissue retractors, vaporization devices, and urinary drainage catheters. In non-metropolitan Appalachian areas of southeastern Ohio, mobile outpatient lithotripsy fleets provide vital stone care, sustaining demand for compact laser units.

Michigan, Indiana, and Wisconsin add notable scale to the Midwestern marketplace. In Michigan, major integrated health networks around Detroit, Ann Arbor, and Grand Rapids utilize centralized purchasing structures to negotiate enterprise contracts for urological consumables, standardizing access sheaths, stone extraction baskets, and guidewires across ambulatory networks. Indiana and Wisconsin present favorable regulatory environments for physician-owned ambulatory facilities, prompting urology groups to open dedicated office-based procedure rooms for diagnostic urodynamics, blue-light cystoscopy bladder surveillance, and in-office BPH therapies.

Minnesota, Missouri, Iowa, Kansas, and the Dakotas reinforce the Midwestern market’s strength. Minnesota stands out as a global epicenter of medical device innovation, fostering early clinical evaluation of cutting-edge outpatient urology platforms across Minneapolis-St. Paul and Rochester. In rural communities throughout Iowa, Kansas, and Nebraska, outpatient clinics rely on dependable, low-maintenance capital equipment, such as air-cooled thulium fiber lasers and durable urodynamic consoles, supported by robust field-service networks and comprehensive remote clinical education programs.

Northeast

The Northeast constitutes a high-value regional market, accounting for USD 0.86 billion in 2026, building upon historical marks of USD 0.68 billion in 2023, USD 0.74 billion in 2024, and USD 0.80 billion in 2025. It is projected to reach USD 1.37 billion by 2032, expanding at a CAGR of 8.07% over the forecast period.

The Northeast is characterized by dense concentrations of world-renowned academic medical centers, high urologist specialist density per capita, comprehensive insurance coverage, and sophisticated clinical research hubs. Although strict certificate-of-need laws in several northeastern states moderate the construction velocity of new independent ambulatory surgery centers, hospital outpatient departments and hospital-owned off-campus outpatient facilities capture significant procedural volumes, deploying premium capital instrumentation and specialized single-use visualization platforms.

New York represents the largest state market in the Northeast, with major health systems in New York City, Long Island, Westchester, and upstate metropolitan centers driving substantial procedural velocity. New York urologists perform large numbers of outpatient retrograde intrarenal surgeries and complex bladder cancer surveillance procedures annually. High operational costs and spatial constraints within metropolitan New York operating suites make single-use digital cystoscopes and compact laser consoles attractive, as they eliminate dedicated endoscope reprocessing rooms and lower fixed facility overhead. Academic networks across the state serve as early evaluators of AI-assisted image analysis platforms for outpatient non-muscle invasive bladder cancer identification.

Pennsylvania is a major healthcare market, anchored by prominent health systems in Philadelphia and Pittsburgh alongside extensive community hospital networks throughout the state. Pennsylvania exhibits an older demographic profile, driving consistent demand for benign prostatic hyperplasia interventions, urinary incontinence slings, and sacral neuromodulation systems. Large multi-specialty ambulatory surgery centers in suburban Philadelphia process high volumes of outpatient lithotripsy, driving steady consumable turnover for pulse-modulated holmium fibers, suction access sheaths, and magnetic-retrieval double-J stents.

Massachusetts exercises substantial clinical influence throughout the region, led by the dense academic and life-sciences ecosystem in Boston and Cambridge. Boston-area teaching hospitals and associated outpatient centers serve as key testing sites for next-generation endourological devices, including robotic-assisted flexible ureterorenoscopy platforms, sub-cellular laser lithotripsy systems, and novel temporary implantable devices for BPH. Massachusetts clinicians demand robust clinical trial data, driving adoption of advanced instrumentation that demonstrates clinical efficacy, reduced operative times, and lower complications in ambulatory settings.

New Jersey, Connecticut, Rhode Island, Maine, New Hampshire, and Vermont complete the northeastern market. New Jersey and Connecticut feature high per-capita incomes and well-insured patient populations who actively seek out the latest minimally invasive therapies for voiding dysfunction and stone disease, prompting suburban urology practices to establish accredited office-based surgical suites. In northern New England, regional hospital networks in Maine, New Hampshire, and Vermont concentrate outpatient urological procedures within specialized ambulatory care centers, relying on standardized single-use endoscopes to streamline logistics across decentralized rural clinics.

Key Market Players

The U.S. Ambulatory Urology Devices competitive arena is moderately consolidated across core therapeutic and visualization platforms, yet remains dynamic and fragmented across specialized niche indications, consumables, and emerging minimally invasive technologies.

The following 15 key players operate within the U.S. ambulatory urology devices market:

Boston Scientific Corporation
Olympus Corporation
Teleflex Incorporated
Coloplast A/S
BD (Becton, Dickinson and Company)
Cook Medical LLC
Stryker Corporation
Karl Storz SE & Co. KG
Richard Wolf GmbH
Ambu A/S
Medtronic plc
Axonics, Inc.
PROCEPT BioRobotics Corporation
Dornier MedTech GmbH
UroViu Corporation

Boston Scientific Corporation commands a leading position across the domestic ambulatory urology space, supported by a comprehensive product portfolio spanning stone management, benign prostatic hyperplasia, and pelvic health. Its commercial presence in stone management is reinforced by its LithoVue single-use digital flexible ureteroscope franchise, paired with the Lumenis laser portfolio, which provides high-power holmium:YAG laser systems with pulse-modulation technology. In BPH, the company’s Rezūm convective water vapor therapy platform dominates office-based ablative procedures, enabling urologists to treat obstructive prostatic tissue under local anesthesia. Boston Scientific backs its hardware with extensive enterprise contracting, specialized clinical training suites, and reimbursement support that aligns with ambulatory surgery center operations.

Olympus Corporation maintains a strong footprint in outpatient endoscopic visualization, electro-resection, and laser lithotripsy. Its portfolio includes high-definition video resectoscopes, the Soltive super-pulsed thulium fiber laser system, and both reusable and single-use digital cysto-ureteroscopy platforms. Soltive has driven significant outpatient adoption due to its compact footprint, standard electrical wall-outlet compatibility, and dust-generating lithotripsy capabilities that shorten operative times. Olympus leverages extensive hospital and ASC relationships, offering flexible capital leasing and structured consumable supply agreements that ease financial barriers for outpatient facilities updating their visualization infrastructure.

Teleflex Incorporated has established a major presence in minimally invasive BPH treatments through its UroLift System. The UroLift prostatic urethral lift platform uses permanent transprostatic implants to mechanically retract obstructing lateral lobes without cutting, heating, or removing prostate tissue. This preserves sexual function and enables rapid, catheter-free recovery in outpatient and office-based settings. Teleflex backs the platform with direct-to-consumer educational campaigns, patient navigation resources, and coding support, maximizing procedural volume across independent urology practices and ambulatory networks.

Coloplast A/S maintains a strong commercial presence focused on endourology consumables, urinary drainage, and interventional pelvic health prosthetics. Its portfolio features hydrophilic-coated double-J ureteral stents, the Isiris single-use digital cystoscope with an integrated stent removal grasper, percutaneous nephrostomy sets, and the Titan inflatable penile prosthesis and suburethral slings. Coloplast excels in outpatient workflow efficiency: products like the Isiris platform combine visualization and mechanical extraction into a single sterile tool, eliminating dedicated operating room setups and reprocessing cycles for routine post-lithotripsy stent removals.

BD (Becton, Dickinson and Company) leverages its enterprise-scale supply chain and expansive distribution network to deliver essential urological consumables, drainage systems, and diagnostic tools to the ambulatory sector. Through its Bard portfolio, BD supplies hydrophilic intermittent catheters, Foley catheter trays, infection-control drainage bags, ureteral navigation guidewires, and mechanical stone retrieval baskets. BD’s clinical strategy focuses on procedure standardization, high-volume inventory reliability, and infection risk reduction, making it a key primary vendor for ambulatory surgery centers and hospital outpatient departments seeking enterprise-level supply chain consolidation.

Cook Medical LLC remains a pioneer in endourology instrumentation and minimally invasive access systems. The company supplies specialized consumables, including the Flexor parallel and radial dilation ureteral access sheaths, nitinol stone retrieval baskets, slip-coated guidewires, and bi-wire dual lumen access systems. Cook Medical prioritizes precision engineering and traumatic tissue safety, providing accessories that maintain optical clarity and stabilize intrarenal pressures during high-frequency laser dusting. Its direct clinical sales model and focused physician training programs maintain strong brand loyalty among ambulatory endourologists.

Stryker Corporation approaches ambulatory urology by integrating advanced operating room infrastructure, visualization platforms, and surgical instrumentation. Stryker delivers 4K camera visualization consoles, LED surgical light sources, high-flow fluid distention pumps, and general outpatient surgical tables that integrate with multi-specialty ambulatory surgery center suites. By bundling urology-specific endoscopes and fluid management tools into broader ASC capital procurement packages, Stryker enables newly developed outpatient surgery centers to acquire integrated surgical suites through unified capital financing structures.

Karl Storz SE & Co. KG is a recognized benchmark for optical quality and precision engineering in rigid and flexible endourology instrumentation. Its portfolio features high-definition Hopkins rod-lens rigid cystoscopes, video resectoscopes, flexible digital video ureteroscopes, and the modular IMAGE1 S camera processor platform. While historically known for durable reusable capital equipment, Karl Storz has expanded into single-use visualization via its CMOS-chip flexible endoscopes. This enables ambulatory centers to blend reusable optical tools with sterile single-use platforms, tailoring equipment selection to patient acuity and room scheduling needs.

Richard Wolf GmbH supplies specialized endourology and extracorporeal shock wave lithotripsy systems to the outpatient market. The company’s portfolio includes the MegaPulse holmium laser series, specialized fiber delivery accessories, flexible and rigid endoscopes, and the Piezolith piezoelectric lithotripsy system. Richard Wolf focuses on precision ergonomics, low maintenance profiles, and durable mechanical designs, making its instruments popular among high-volume ambulatory centers and outpatient stone clinics seeking low total cost of ownership.

Ambu A/S is a leader in single-use visualization, driving the transition from reusable scopes to sterile, disposable platforms. Its aScope 4 Cysto platform provides ambulatory surgery centers and urology clinics with ready-to-use, single-use flexible cystoscopes featuring high-resolution imaging and responsive mechanical articulation. Ambu eliminates scope reprocessing infrastructure, high-level disinfection chemicals, and mechanical repair bills, offering a fixed, predictable per-procedure cost model. This economic framework aligns with outpatient clinics seeking to increase daily diagnostic throughput and eliminate cross-contamination risks.

Medtronic plc maintains a strategic position in outpatient voiding dysfunction and functional urology through its sacral neuromodulation and advanced energy portfolios. Its InterStim system—featuring both the InterStim II recharge-free neurostimulator and the miniature InterStim Micro rechargeable system—is a standard therapeutic option for treatment-refractory overactive bladder, non-obstructive urinary retention, and chronic fecal incontinence. Medtronic supports outpatient urology with refined surgical toolkits that enable lead placement and stimulator pocket insertion under local anesthesia in under 30 minutes, keeping procedures within ambulatory surgery center settings.

Axonics, Inc. has driven technological competition in the sacral neuromodulation and urinary incontinence market through continuous innovation in miniaturized implants and urethral bulking agents. Its sacral neuromodulation platform includes compact rechargeable and long-lasting recharge-free neurostimulators, supported by an intuitive touchscreen patient programmer and simplified programming interfaces. Axonics also supplies Bulkamid, an injectable polyacrylamide hydrogel for female stress urinary incontinence that can be administered via office-based cystoscopy in under 15 minutes. Axonics’ focus on ease of use, long implant lifespans, and direct-to-consumer education has accelerated the adoption of outpatient incontinence therapies nationwide.

PROCEPT BioRobotics Corporation is transforming surgical BPH management within outpatient and ambulatory environments through its AquaBeam Robotic System, which delivers Aquablation therapy. Combining real-time multi-dimensional ultrasound imaging with computer-controlled, high-velocity saline waterjet resection, Aquablation provides predictable, heat-free surgical tissue removal regardless of prostate size or anatomical morphology. PROCEPT BioRobotics has adapted its clinical protocols and capital financing programs to facilitate Aquablation adoption within high-volume ambulatory surgical centers, enabling surgeons to achieve precise tissue resection with short operative times and same-day discharge.

Dornier MedTech GmbH maintains an established position in urinary stone management, recognized for its extracorporeal shock wave lithotripters and specialized surgical laser systems. Its product line features the Delta III shock wave lithotripsy platform and the Thulium Fiber Laser series, designed specifically for rapid dusting and stone vaporization. Dornier combines capital device manufacturing with mobile service routes and equipment leasing programs, allowing community-based ambulatory surgery centers and outpatient clinics to offer advanced laser and shock wave lithotripsy without large upfront capital outlays.

UroViu Corporation is an innovator in single-use micro-endoscopy, delivering portable, self-contained diagnostic and interventional cystoscopes to outpatient and office-based urology practices. UroViu’s platforms feature an ultra-lightweight, battery-powered handle with an integrated display screen, pre-sterilized modular cannulas, and versatile working channels that bypass the need for external video towers, light cables, or display monitors. By miniaturizing diagnostic visualization into a handheld form factor, UroViu enables practitioners to perform immediate cystoscopies and stent retrievals within standard examination rooms, optimizing clinical workflow and eliminating equipment bottlenecks in busy practices.

Recent Developments

The U.S. ambulatory urology devices market has experienced significant clinical, corporate, and regulatory activity, underscoring the rapid shift of interventions into outpatient and office settings.

Regulatory clearances have expanded the clinical scope of minimally invasive therapies for benign prostatic hyperplasia. Over the 2024–2026 timeframe, the FDA granted 510(k) clearances and pre-market approvals for next-generation convective water vapor delivery shafts, expanded anatomical size indications for the temporary implantable nitinol device, and upgraded ultrasound-guided robotic waterjet ablation platforms. These regulatory expansions allow urologists to treat median lobe obstructions and larger prostate volumes exceeding 80 to 100 grams within ambulatory surgical centers, cases that historically mandated inpatient open or transurethral surgery.

Strategic acquisitions have reshaped competitive positioning across stone management and pelvic health. Medical device leaders have moved to acquire niche innovators specializing in single-use endoscopes, steerable access sheaths, and intelligent laser delivery fibers. Corporate consolidators have integrated novel continuous-suction access sheaths designed to maintain low intrarenal pressures during high-frequency dusting. These technologies help prevent systemic fluid absorption, reducing post-operative complications and emergency room returns following outpatient ureteroscopy.

Concurrently, production and clinical adoption of single-use digital cystoscopes and ureteroscopes have accelerated. Responding to updated infection-control guidelines and high-level disinfection costs issued by health authorities and urological associations, hospital outpatient departments and independent ambulatory surgery centers have converted substantial portions of their visualization fleets to sterile single-use platforms. Manufacturers have introduced single-use scopes featuring outer diameters down to 7.5 French, integrated LED illumination, and dynamic bidirectional tip deflection, matching the optical clarity and maneuverability of legacy reusable models while eliminating repair budgets.

Reimbursement policy updates from CMS have further propelled outpatient market expansion. Modifications to the Ambulatory Surgical Center Covered Procedures List and recalibrations within the Outpatient Prospective Payment System have improved facility fee payments for complex endourological stone interventions, robotic-assisted waterjet tissue resections, and sacral neuromodulation lead placements. Concurrently, targeted updates to Physician Fee Schedule non-facility practice expense values for office-based prostatic urethral lifts and transurethral water vapor therapy have reinforced the financial viability of independent, in-office surgical suites, shielding private urology practices from acute-care hospital system control.

Technological progress in laser lithotripsy has seen the broad commercial deployment of high-frequency thulium fiber lasers alongside pulse-modulated holmium:YAG platforms across outpatient facilities. These advanced systems provide dusting pulse frequencies exceeding 2,000 Hertz, pulverizing urinary calculi into micro-particulate dust that eliminates the need for mechanical basket retrieval. Because thulium fiber lasers feature compact designs, operate from standard 120-volt electrical outlets, and require standard air cooling, ambulatory surgery centers have installed these consoles without the expensive electrical and structural renovations demanded by legacy water-cooled laser systems.

Finally, private-equity-driven consolidation of independent urology practices has accelerated across the South, Midwest, and Western regions. Regional urology management organizations have built state-of-the-art ambulatory surgery centers and specialized office-based surgical suites. By aggregating surgical volume and standardizing procedural protocols on modern, single-use, minimally invasive platforms, these provider networks maximize patient throughput, negotiate favorable group purchasing agreements with medtech manufacturers, and systematically redirect cases away from hospital inpatient departments.

Conclusion

The U.S. Ambulatory Urology Devices Market is positioned to expand from USD 5.36 billion in 2026 to USD 9.29 billion by 2032, advancing at a CAGR of 9.65% from 2027 to 2032. Historical market progression from USD 4.12 billion in 2023 to USD 4.90 billion in 2025 demonstrates a structural transformation in urological healthcare delivery, characterized by the steady migration of procedures from inpatient hospital suites to lower-cost, highly efficient ambulatory environments.

This market expansion is underpinned by demographic realities and technological convergence. An aging male population with high rates of benign prostatic hyperplasia, combined with recurring nephrolithiasis across the domestic Stone Belt and rising voiding dysfunction prevalence, generates deep clinical demand. Simultaneously, innovations in single-use digital visualization, compact dusting lasers, micro-invasive tissue debulking implants, and miniaturized neuromodulation systems have made outpatient interventions safer, more reproducible, and clinically preferable to traditional inpatient surgeries.

Ambulatory surgery centers will remain the primary volume engine for complex stone removal, enucleation, and prosthetic implants, while office-based surgical suites represent the fastest-growing procedural venue for rapid BPH therapies and diagnostic evaluations. Across all outpatient environments, single-use disposable devices will continue to take market share from reusable instruments, driven by favorable workflow economics, the total elimination of scope reprocessing and repair costs, and zero risk of cross-patient contamination.

Regionally, the South maintains the largest commercial footprint, supported by concentrated stone disease prevalence, an expanding retiree base, and a business climate that favors ambulatory surgery center construction. The West will lead in technology-driven growth, propelled by early clinical adoption of digital health platforms and single-use visualization tools. The Midwest combines deep demographic disease burden with health-system outpatient consolidation, while the Northeast continues to invest in advanced visualization platforms and academic outpatient care.

For medical device manufacturers, clinical operators, and healthcare investors, strategic success will hinge on delivering integrated, workflow-optimized procedural ecosystems. Competitive advantage will belong to organizations that unite reliable capital hardware with high-margin disposable consumables, offer flexible, per-procedure commercial models, and provide robust coding and reimbursement support to maximize provider economic efficiency. By lowering procedural friction, minimizing operating room turnaround times, and supporting rapid patient convalescence, the ambulatory urology sector stands as one of the most commercially resilient and technologically dynamic arenas in modern American healthcare.